Pancreatic Cancer Research

ResearcherZhujiang HospitalActive in the last 2 years

Chihua Fang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1653-0711; OpenAlex author ID A5102871497. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
9
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 3

  1. CX26 promotes pancreatic cancer progression by competitively inhibiting interaction of c-Myc with PSMD2 and enhancing c-Myc stability. Last author DOI 10.1186/s12967-025-06983-5↗
  2. Review and Application of Integrin Alpha v Beta 6 in the Diagnosis and Treatment of Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1177/15330338231189399↗
  3. Targeting carbon nanotubes based on IGF-1R for photothermal therapy of orthotopic pancreatic cancer guided by optical imaging. Co-author DOI 10.1016/j.biomaterials.2018.12.025↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qing Zhu · 1 shared paper, 2025 · strength 0.30
  2. Cheng He · 1 shared paper, 2025 · strength 0.30
  3. Yunyu Lian · 1 shared paper, 2023 · strength 0.22
  4. Ning Zeng · 1 shared paper, 2023 · strength 0.22
  5. Guanhua Lu · 1 shared paper, 2019 · strength 0.09
  6. Yingfang Fan · 1 shared paper, 2019 · strength 0.09
  7. Xiaoyuan Liang · 1 shared paper, 2019 · strength 0.09
  8. Ziyu Han · 1 shared paper, 2019 · strength 0.09
  9. Jie Tian · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.